Statin associated adverse reactions in Latin America: a scoping review
Open Access
- 1 October 2021
- Vol. 11 (10), e050675
- https://doi.org/10.1136/bmjopen-2021-050675
Abstract
Objectives We aim to describe the frequency and type of adverse drug reactions (ADRs) in patients on statins in published studies from Latin American (LATAM) countries. Design Scoping review. Methods A literature search was conducted in three databases (PubMed, EMBASE and LILACS) in addition to a manual search in relevant journals from LATAM universities or medical societies. A snowballing technique was used to identify further references. Randomised controlled trials (RCTs) and observational studies between 2000 and 2020 were included. Studies were considered eligible if they included adults on statin therapy from LATAM and reported data on ADRs. Data on ADRs were abstracted and presented by study design. Results Out of 8076 articles, a total of 20 studies were included (7 RCTs and 13 observational studies). We identified three head-to-head statin RCTs, two statin-versus-policosanol RCTs and only two placebo-controlled trials. The statin-related ADRs frequency ranged from 0% to 35.1% in RCTs and 0% to 28.4% in observational studies. The most common ADRs were muscle-related events including myalgia and elevated creatine phosphokinase. Other reported ADRs were gastrointestinal symptoms, headache and altered fasting plasma glucose. Conclusions We identified differences in the frequency of ADRs in both observational studies and RCTs from LATAM countries. This could be due to the absence of standard definitions and reporting of ADRs as well as differences among the study’s interventions, population characteristics or design. The variability of ADRs and the absence of definitions are similar to studies from other geographical locations. Further placebo-controlled trials and real-world data registries with universal definitions should follow.This publication has 60 references indexed in Scilit:
- Muscular effects of statins in the elderly female: a reviewClinical Interventions in Aging, 2013
- Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trialAmerican Heart Journal, 2011
- Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?Canadian Journal of Cardiology, 2011
- Scoping studies: advancing the methodologyImplementation Science, 2010
- Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 PatientsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatinCurrent Medical Research and Opinion, 2005
- How to spot bias and other potential problems in randomised controlled trialsJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Comparison of the Efficacy, Safety and Tolerability of Policosanol versus Fluvastatin in Elderly Hypercholesterolaemic WomenClinical Drug Investigation, 2001